The chronic obstructive pulmonary disease (COPD) market was valued at $21.6 billion in 2023 and is projected to grow to $33.29 billion by 2033. This growth represents a strong compound annual growth rate (CAGR) of 4.42% from 2024 to 2033.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5154
The chronic obstructive pulmonary disease (COPD) market encompasses all areas related to COPD, including research, drug development, diagnosis, treatment, monitoring, and post-treatment care. COPD is a widespread lung condition that limits airflow and causes breathing difficulties. Patients often experience lung damage and the buildup of phlegm, leading to symptoms like coughing, wheezing, fatigue, and sometimes excessive mucus production.
Tobacco use and air pollution are the main contributors to COPD. Although there is no cure, symptoms can be alleviated by quitting smoking, avoiding pollutants, and getting vaccinated to prevent infections. COPD is also managed with treatments like oxygen therapy, medications, and pulmonary rehabilitation. Since COPD is a chronic condition requiring continuous care, the market for its treatment is steadily growing. The increasing prevalence is driven by factors such as smoking, pollution, and workplace hazards.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/chronic-obstructive-pulmonary-disease-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5154
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More